Investors & Media

Stock Info
Our Story

Inhibitor Therapeutics, we are a publicly traded, clinical stage pharmaceutical development company. We have a focus on developing and commercializing innovative therapies, using repurposed, already approved API’s (active pharmaceutical ingredients) that have clinical value and are patent protected. We have a significant amount of owned intellectual property around the use of itraconazole in oncology indications, especially in the treatment of Basal Cell Carcinoma Nevus Syndrome and both lung and prostate cancers.

Recent News
Dec 19, 2023

Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application ("NDA") to FDA TAMPA, Fla., Dec. 19, 2023...

Dec 13, 2023

A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc....

Events & Presentations
Get Important News and Updates by Email
* Required Fields